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Antibiotics are a critically important part of paediatric medical care in low- and middle-income countries (LMICs), where infectious
diseases are the leading cause of child mortality. The World Health Organization estimates that >50% of all medicines are prescribed,
dispensed or sold inappropriately and that half of all patients do not take their medicines correctly. Given the rising prevalence of
antimicrobial resistance globally, inappropriate antibiotic use is of international concern, and countries struggle to implement basic
policies promoting rational antibiotic use. Many barriers to rational paediatric prescribing in LMICs persist. The World Health
Organization initiatives, such as ‘Make medicines child size’, the Model List of Essential Medicines for Children and the Model Formulary
for Children, have been significant steps forward. Continued strategies to improve access to appropriate drugs and formulations, in
conjunction with improved evidence-based clinical guidelines and dosing recommendations, are essential to the success of such
initiatives on both a national and an international level. This paper provides an overview of these issues and considers future
developments that may improve LMIC antibiotic prescribing.
Introduction
In low- and middle-income countries (LMICs), the diagno-
sis of serious bacterial infections usually relies on clinical
judgement without the benefit of diagnostic tests avail-
able elsewhere. Rapid access to effective antibiotics plays
a critical role in improving outcomes in this setting. There
is a well-established association at the population level
between antibiotic consumption and antimicrobial resist-
ance (AMR) [1]. Rational antibiotic prescribing is a central
component of strategies to limit the spread of AMR glob-
ally [2]. While prescribing practices have generally been
well documented in high-income countries, there are
limited data for LMICs. The World Health Organization
(WHO) estimates that >50% of all medicines are pre-
scribed, dispensed or sold inappropriately and that half of
all patients fail to take medicines correctly [3]. Many coun-
tries do not implement basic policies to promote rational
antibiotic use [4], and <40% of patients with infections are
treated according to clinical guidelines [5].
Historically, simple access to effective medicines for
children in LMICs has also been challenging. However, fol-
lowing almost universal adoption of the World Health
Assembly resolution WHA 60.20 ‘Better Medicines for Chil-
dren’ and the subsequent launch of the WHO initiative
‘Make medicines child size’ in 2007 [6], there have been
some landmark developments; these include the WHO
Model List of Essential Medicines for Children (EMLc) [7]
and the WHO Model Formulary (WHO MF) for Children [8].
Meanwhile, despite the consensus that AMR continues
to pose a global threat, national and global responses
remain inadequate. From the child health perspective,
there is a lack of national and international neonatal- and
paediatric-specific AMR surveillance data, which limits the
development of evidence-based guidelines and the imple-
mentation of effective prevention measures. As there are
very few new antibiotics in the late stages of the drug-
development pipeline, it is critical to make best use of
existing antibiotics to preserve their efficacy for as long
as possible [2, 9]. In 2011, the WHO published a policy
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package identifying key strategies required to combat
AMR (summarized in Box 1).
This review summarizes the current issues relating to
rational antibiotic prescribing for children in LMICs. We
focus particularly on the challenges of improving antibi-
otic prescribing, as these remain the drugs most widely
prescribed for children in this setting.
Antibiotic consumption and
antimicrobial resistance
Understanding the extent of antibiotic consumption is an
essential starting point for strategies aimed at improving
rational antibiotic use, but quantifying antibiotic con-
sumption in LMICs is itself challenging, particularly so in
children [10]. Methods used for the study of antimicrobial
consumption in adults, such as the ATC/DDD (Anatomical
Therapeutic Classification/Defined Daily Dose) methodol-
ogy [11], fail to reflect variation in paediatric dosing with
bodyweight and surface area. The existing studies of LMIC
paediatric antibiotic consumption indicate the scale of the
problem. Methodological differences make comparisons
difficult [10]. The Antimicrobial Resistance and Prescribing
in European Children (ARPEC) study recently published
initial results of a large international point prevalence
survey using a standardized methodology [12]. Of the
institutions from LMICs included (almost all of them teach-
ing hospitals), the proportion of children prescribed
antibiotics ranged from ∼40 to 60%. The establishment
of this methodology facilitates meaningful comparisons
between similar institutions and geographical regions, as
well as the examination of prescribing trends.
An estimated 80% of all antibiotic prescribing occurs in
the community [13]. Systematic data on community anti-
biotic prescribing in relation to children in LMICs is very
sparse. A large WHO study of community prescribing
highlighted significant variation in prescribing by type of
healthcare facility and by geographical location. The study
encountered significant methodological and logistical
challenges in collecting data, and there were no data spe-
cifically relating to children [14]. Furthermore, it is also
recognized that there is often a wide difference in the
prescribing practice between individual countries/regions
defined as LMICs. Exploration of these regional variations
is beyond the scope of this review, because the available
data are very limited to date.
World Health Organization
model list of essential medicines
for children
Given that the availability of medicines is known to influ-
ence rational drug consumption, an important step
forward has been the development of an essential medi-
cines list (EML). The EMLs are designed to be country spe-
cific and based on local knowledge of disease prevalence
and resistance factors. However, since its development
in 1975, the distinct needs of children had been largely
ignored, until the EMLc was established in 2007.
The EML aims to identify the core medicines required
to cover the most common clinical needs. There is a strong
emphasis on the requirement for national policy decisions,
with local ownership and implementation. In addition,
a number of guiding principles for essential drug pro-
grammes have emerged. An explicit formulary should
ensure that therapeutic choices are consistent and cost
effective and should help to ensure adequate supply. This
will also enable national pricing negotiations to ensure
that generic medicines are supplied at market rates.
There are several issues with EMLs; for example, current
evidence suggests that although 70% of WHO member
nations adopt the EML concept, only 30% employ EMLs
to influence reimbursements and procurements [15].
Although evidence suggests that the use of positive for-
mulary lists reduces prescription rates in the short term,
there is a lack of data regarding their long-term effects
[16]. Strategies such as limiting branded products to one
or two per therapeutic class have yet to be rolled out inter-
nationally. Denmark follows this policy, managing 4900
branded drugs compared with 10 000 in the UK and 23 000
in Germany [16].
Cost, accessibility and availability
Medicine budgets pose a high economic burden on
households and health systems, accounting for 60–90% of
household expenditure and 25–65% of public and private
expenditure in LMICs [17]. Correct access to essential
medicines would potentially save up to 10.5 million lives
Box 1
The World Health Organization’s policy package to combat
antimicrobial resistance (adapted from Leung et al. [2])
Commit to a comprehensive, financed national plan
with accountability and civil society engagement
Strengthen surveillance and laboratory capacity
Ensure uninterrupted access to essential medicines of
assured quality
Regulate and promote rational use of medicines,
including use in animal husbandry, and ensure
proper patient care
Enhance infection prevention and control
Foster innovations and research and development for
new tools
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per year [18]. The World Trade Organization Declaration on
the Trade Related Aspects of International Property Rights
(TRIPS) agreement (the Doha agreement, 2001) made it
possible for countries to maintain medicines at affordable
levels and thus protect public health. However, imple-
menting these rights is problematic due to complex tariffs
and health service priorities.
Up to 90% of the population in LMICs purchase medi-
cines through out-of-pocket payments, making medicines
the largest family expenditure item after food. As a result,
medicines are unaffordable for large sections of the global
population [19]. Financial pressures often mean that
patients may purchase medicines on a daily basis, so
courses of treatment are frequently not completed or not
even started at all. Additionally, patients may store antibi-
otics from uncompleted courses, well beyond the expiry
date, and later take them for self-diagnosed conditions
or give them to family members and friends [20, 21]. In
one study, 60% of Chinese parents had administered
unprescribed antibiotics to their children [22]. This has
important implications for antimicrobial resistance and
needs to be considered by all practitioners. The overuse of
cheap, broad-spectrum antibiotics in addition to poverty
and overcrowding will continue to foster antimicrobial
resistance in this setting.
In 2001, a resolution endorsed by WHO Member States
called for the development of a standardized method for
measuring medicine prices, which resulted in the launch
of the WHO/Health Action International (HAI) Project on
Medicine Prices and Availability [23]. The project aims to
contribute to target 17 of the Millennium Development
Goals: ‘in cooperation with pharmaceutical companies, [to]
provide access to affordable, essential drugs in developing
countries’. The WHO/HAI methodology aimed to sample
a list of 30 medicines deemed essential to treat a range
of common conditions (acute and chronic) that cause
substantial mortality and morbidity. Of the antibiotics
included in this survey, ciprofloxacin was identified in 96%
of surveyed countries and amoxicillin, ceftriaxone and
cotrimoxazole in 89%. The availability of these antibiotics
varied by drug and by region. Generic brands were poorly
available in the public vs. private sector in low-income
countries (36.1% in low-income vs. 44.3% in low-middle-
income countries and 76.3% in the private sector). At the
same time, the median price range for generics in the
public sector was 1.1 times the international reference
pricing, with African prices averaging 34–44% more than
international reference prices [23].
A study on key medicines for children included in
national EMLs and treatment guidelines, which also
assessed the availability of these medicines in 14 countries
in central Africa, found availability to be poor [24]. Only
three countries had >50% of key paediatric medicines
available from central medical stores at the time of the
survey. Private pharmacies tended to have more medicines
in stock than primary healthcare clinics. Additionally, pae-
diatric formulations are usually more expensive than the
adult equivalents, which leads to inappropriate or unsafe
use of adult dosage forms [25]. This would appear to
suggest that enforcing low pricing would have a beneficial
effect on availability and accessibility. However, caution is
essential as, paradoxically, reducing the price may provide
a disincentive to stock low-priced generics at the point
of purchase in favour of higher-priced branded products
[23].
For those fortunate enough financially to access anti-
biotics, there are further obstacles. Two-thirds of antibiot-
ics are sold over the counter, without written prescriptions
[26]. Consumers can therefore purchase antibiotics for self-
diagnosed problems without any medical consultation.
In many settings, oversupply in an alternative marketplace
further complicates the supply chain. Easily available
medicines can artificially inflate consumer demand and,
consequently, drug availability and pricing. These factors
affect the ability of healthcare facilities to maintain stocks
of essential medicines and of governments to plan
healthcare expenditure. Where antibiotics are freely avail-
able, alternative (nonmedical) sellers are often the first
point of call [27]. The inadequate regulation of antimicro-
bial supplies has important consequences for AMR, espe-
cially in LMICs where antibiotic choices are often limited.
Selective pressure control strategies, such as antimicrobial
cycling or the banning of monotherapy of partner drugs
when used in combination therapy, depend on compli-
ance with drug-use regulations. Overuse of antibiotics
needs to be tackled through a combination of increased
public awareness, training of pharmacists, legislation and
adequate enforcement and monitoring of antimicrobial
use and resistance.
Counterfeit medicines
Control of the quality of antimicrobial agents is vital for the
delivery of effective therapy. Lower-than-stated doses in
antibiotics can result in selection of drug-resistant strains
as well as therapeutic failure. Counterfeit drugs have been
estimated to account for 6–20% of all drug sales and are
most commonly antibiotics [28]. In a systematic review of
the availability of counterfeit and substandard antibiotics
in LMICs, the median prevalence was 28.5%, with inad-
equate amounts of active ingredients found in 93% of
studies [29]. Counterfeit medications (which also include
expired drugs accessible to patients) represent only one
class of substandard medications. Other products are inad-
vertently manufactured at substandard quality or ren-
dered partly or totally inactive due to improper storage.
Many antibiotics are heat and moisture labile and there-
fore liable to deteriorate in ambient tropical conditions
[30]. Appropriate storage is expensive and requires train-
ing; in some cases, reformulating preparations specifically
for tropical countries is theoretically desirable [31]. To our
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knowledge, studies assessing the link between antibiotic
quality and AMR have not been documented, and this
issue deserves further investigation.
Evidence-based prescribing
guidelines – choice of drug
The choice of an appropriate antibacterial agent, dose
and optimal duration of therapy depends on a number
of variables, including the site of infection, host factors,
bioavailability and palatability of the medication, local
resistance patterns and, importantly, knowledge of the
infectious agent. In paediatric practice, especially in LMICs,
diagnoses of infectious syndromes are often based
solely upon symptoms and signs. Clinical specimens to
identify causative agents are not, or cannot, be practicably
obtained for many infections. Clinicians diagnose and treat
syndromes often without knowledge of whether the
causative organism is bacterial. This makes the decision of
whether to treat and with which antibiotic challenging,
and probably contributes to the heterogeneity of results
from clinical trials and guidelines.
Standard treatment protocols have been developed
to aid clinical decision making and have been shown to
improve rational prescribing [32]. The WHO Drug Action
Programme ‘Guide to Good Prescribing’ aims to enhance
clinician education by providing a framework that pro-
motes an evidence-based approach to prescribing [33].
The goal is to use antibiotics with proven efficacy and
safety data, with consideration of the rationale behind the
choice of drug, its cost and its pharmacokinetic proper-
ties. In order to study, monitor and assess prescribing
practices uniformly, the WHO has created a protocol
based on recommendations by Laing et al. [4]. In a study
of Gambian prescribing practices using this protocol and
a global review of the literature, Risk et al. [34] highlighted
extensive variations in antibiotic prescribing, with sub-
stantial overprescription of antibiotics for common child-
hood illnesses. Their review highlighted the low number
of drugs prescribed according to EML in Asia (38.9% in
India and 56.5% in Nepal) compared with Tanzania
(93.1%), Sudan (73.5%) and Gambia (95%); >50% of child-
hood fever encounters resulted in the prescription of anti-
biotics [34].
The WHO Pocket Book of Hospital Care for Children
offers guidance on clinical diagnosis and management
of suspected severe bacterial infections in children in
resource-poor settings [35]. Whilst the second edition has
the useful introduction of a blank front page for local anti-
biotic guidelines, the generic recommendations list only
eight major antibiotics (Table 1) for the treatment of all
severe bacterial infections in childhood. Therefore, to
avoid selective pressure, these drugs must be used ration-
ally in conjunction with appropriate guidelines. Such
protocols should ideally be evaluated in clinical trials
to determine whether efficacy can be maintained while
reducing the propensity for resistance.
Appropriate dosing
Paediatric formularies and
dosing recommendations
When prescribing medicines for children, it is important to
consider not only what the most appropriate drug is, but
also what are the right dose and duration of therapy [36].
In addition to accessing the medicines themselves, access
to accurate, up-to-date dosing information can be difficult
in LMICs. However, the advent of the WHO Model Formu-
lary for Children mentioned above has brought significant
advantages [8]. This formulary is freely accessible online
and also available in paper copies. The medicines listed
match up with the second EMLc [37] and provide dosing
guidance as recommended by the WHO Expert Committee
on the Selection and Use of Essential Medicines [8]. Other
paediatric and neonatal formularies are available [38–40],
some of which have specific schemes to enable access
from LMICs, such as the British National Formulary for
Children (BNFC), which is electronically accessible free
of charge to developing nations included in the WHO’s
HINARI programme [38, 41].
Nevertheless, ensuring reliability of access to either
online or paper versions of formularies can be challenging
in LMICs. Another source of information is the dosing
guidance provided within the summary of product char-
acteristics that should be enclosed in the packaging of
authentic medicinal products. Unfortunately, paediatric
dosing information can be absent from the summary of
product characteristics, or unclear, or lacking a high-
quality evidence base [42]. This relates to the fact that
unlicensed and off-label use of medicines is widespread in
paediatric clinical practice throughout the world [43]. A
variety of paediatric medicines initiatives have been devel-
oped to address these issues, but there is still much pro-
gress to be made [44].
Establishing the correct weight and the
right dose
Assuming that access to a dosing guideline is achieved,
then the recommended dose may relate to the age of
the child (for age-band-based dosing), the bodyweight
(weight-bands or milligram per kilogram dosing) or the
body surface area. It is not always possible to know the age
or bodyweight of a child in an LMIC setting, where cali-
brated scales are often unavailable, so pragmatic solutions
are essential, particularly in emergencies. When age is
known, then age-based formulae can be used for dosing,
including the advanced paediatric life support (APLS)
and Nelson’s formulae [45]. In an emergency, alternative
methods may be employed, such as the Broselow Tape,
which can estimate bodyweight, tracheal tube size and
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drug dosages based on body length [46]. However, the
accuracy of this method in different geographical popula-
tions and different age groups has been shown to vary
[47, 48]. A recent innovation is the ‘Mercy TAPE’, which
allows improved accuracy and robustness of paediatric
bodyweight estimation; the principle is based on the
‘Mercy method’ using surrogate anthropometric meas-
ures, namely mid-upper arm circumference for body
habitus and humeral length for height [49]. In LMICs,
broadening access to simple devices such as the Broselow
or Mercy TAPE could facilitate significant improve-
ments in the reliability of bodyweight-based dosing for
children.
When no dosing information for children is to hand,
clinicians in LMICs may want a quick calculation to convert
the adult dose to an appropriate dose for children. Histori-
cally, different calculations have been used for this
purpose, based on age, bodyweight or body surface area;
the majority of calculations are not used routinely and are
summarized elsewhere [50]. Some have recommended
using the ‘Salisbury Rule’ approach, as follows:
‘Up to 30 kg, a child’s drug dose may be (Wt × 2)% of
adult dose, Over 30 kg, a child’s drug dose may be (Wt
+ 30)% of adult dose’,
as this can produce results that are similar to the British
National Formulary/British National Formulary for Children
guidelines [50].
However, the use of calculations and equations is
known to increase the risk of medication errors [51]. There
is also an ongoing debate regarding the best methodol-
Table 1
Antibiotic generic recommendations from the World Health Organization pocket book of hospital care [35]
Condition Drug Dose
Dysentery Ciprofloxacin oral 15 mg kg−1 BD for 3 days
Second line: ceftriaxone IV 50–80 mg kg−1 daily for 3 days
Mastoiditis Cloxacillin/flucloxacillin IV
Second line: ceftriaxone IV
50 mg kg−1 QDS for 10 days
Meningitis 1 Ceftriaxone IV or 50 mg kg−1 BD for 7–10 days
2 Cefotaxime IV or 50 mg kg−1 QDS for 7–10 days
3 If no known resistance locally to chloramphenicol and β-lactams:
chloramphenicol IV plus 25 mg kg−1 QDS for 10 days
ampicillin IV or 50 mg kg−1 QDS for 10 days
chloramphenicol IV plus
benzylpenicillin IV 60 mg kg−1 (100 000 U kg−1) QDS for 10 days
Osteomyelitis Cloxacillin/flucloxacillin IV if >3 years old
Second line: ceftriaxone IV or clindamycin IV
50 mg kg−1 QDS (IV therapy for 10 days then switch to oral)
Otitis media, acute Amoxicillin oral 40 mg kg−1 BD for 5 days
Or where there is no known resistance to co-trimoxazole
then give oral co-trimoxazole 4 mg kg−1 trimethoprim plus 20 mg kg−1 sulfamethoxazole BD for 5 days
Infant sepsis and
meningitis
Ampicillin IV plus 50 mg kg−1 QDS for 7–10 days (3 weeks for meningitis)
gentamicin IV or 5–7.5 mg kg−1 daily for 7–10 days (3 weeks for meningitis)
ceftriaxone IV (also plus gentamicin, dose as on line above) 50 mg kg−1 daily for 7–10 days (3 weeks for meningitis)
If staphylococcal infection is suspected, flucloxacillin IV 50 mg kg−1 QDS for 7–10 days (3 weeks for meningitis)
plus gentamicin IV 5–7.5 mg kg−1 daily for 7–10 days (3 weeks for meningitis)
Older child sepsis Ampicillin IV plus 50 mg kg−1 QDS for 7–10 days
gentamicin IV or 7.5 mg kg−1 daily for 7–10 days
ceftriaxone IV monotherapy 50 mg kg−1 daily for 7–10 days
If staphylococcal infection is suspected, flucloxacillin IV 50 mg kg−1 QDS for 7–10 days
plus gentamicin IV 7.5 mg kg−1 daily for 7–10 days
Typhoid Ciprofloxacin oral 15 mg kg−1 BD for 7–10 days
Second line: ceftriaxone IV or 80 mg kg−1 daily for 5–7 days
azithromycin oral 20 mg kg−1 daily for 5–7 days
Urinary tract infection Co-trimoxazole oral 10 mg kg−1 trimethoprim plus 40 mg kg−1 sulfamethoxazole BD for 5 days
Second line: ampicillin IV plus gentamicin IV As for sepsis
Pneumonia Ampicillin IV plus 50 mg kg−1 QDS for at least 5 days
gentamicin IV or 7.5 mg kg−1 daily for at least 5 days
Second line: ceftriaxone IV 80 mg kg−1 daily for at least 5 days
If staphylococcal infection is suspected, cloxacillin IV 50 mg kg−1 QDS for 7–10 days then switch to oral cloxacillin (3 weeks
therapy in total)
plus gentamicin IV 7.5 mg kg−1 daily for at least 5 days
BD, twice daily; IV, intravenous; TDS, three times daily; QDS, four times daily.
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ogy to derive paediatric dosing recommendations [52].
Nonetheless, once the dose for the child has been decided
(whether using the formulary, summary of product char-
acteristics or dose calculation), then administering this
dose will depend on access to an appropriate formulation,
which again is not always possible, as discussed further
below.
Duration of therapy
Reducing the duration of antibiotic therapy has a number
of advantages, namely increasing patient adherence,
decreasing cost and minimizing antimicrobial resistance
[53]. Several studies have highlighted that shorter duration
of therapy may be feasible. Schrag et al. showed that by
using a high-dose short course amoxicillin regimen, overall
exposure of patients’ flora to the antimicrobial agent was
reduced [54]. Kerrison et al. demonstrated that carriage of
penicillin- and co-trimoxazole-resistant pneumococci was
lower in paediatric patients receiving 90 mg kg−1 day−1 of
amoxicillin for 5 days than for those receiving 40 mg kg−1
day−1 for 10 days [53]. Following a multinational ran-
domized controlled trial, Molyneux et al. concluded that
5 days of treatment may be sufficient for the treatment of
bacterial meningitis in LMICs. However, critics have ques-
tioned whether these results are applicable globally and
call for further research into therapy duration for severe
bacterial infections, including meningitis [55].
Biomarkers
Novel diagnostics may aid in risk stratification of serious
bacterial infections and in treatment duration decisions.
In paediatrics, biomarkers such as C-reactive protein and
procalcitonin are useful tools to guide commencement
and cessation of antibiotic therapy [56, 57]. However, their
usefulness outside of lower respiratory tract infections
has yet to be evaluated fully. The development of near-
patient testing technologies for distinguishing bacterial vs.
nonbacterial infections, such as the successful use of rapid
diagnostic tests (RDTs) for malaria in reducing inappropri-
ate antimalarial use, are a potential step in the right direc-
tion [58]. However, although RDTs aim to improve care in
malaria-endemic settings, a negative RDT increases antibi-
otic use as clinicians consider alternative causes of acute
febrile illness [59]. The integration of new RDT technolo-
gies for bacterial infections should therefore be used in
conjunction with rational decisions on the appropriate-
ness of antibiotic therapy if a significant increase in antibi-
otic consumption is to be avoided.
Formulation issues
Access to age-appropriate formulations of medicines for
children can be problematic in both developing and devel-
oped countries [60]. Indeed, one of many issues raised by
EMLs is the fact that most do not contain paediatric formu-
lations, thus hindering supply and availability [61]. Most
medicines are initially developed for adults, and the major-
ity are available only in solid-dosage forms [62]. Children at
different stages of development may be unable to swallow
solid-dosage forms, so liquid formulations are essential
[63]. Although these issues are not restricted to antibiotics
alone, the importance of formulations deserves specific
consideration in this context because these are the most
widely prescribed class of medicines in paediatrics. Antibi-
otic formulation palatability has also been identified as
a major determinant of prescription decision and compli-
ance in LMICs [64].
Age-appropriate formulations are frequently unavail-
able commercially, so are made locally as ‘extemporane-
ous preparations’ [65]. Duncan et al. recently evaluated the
WHO MF for children to assess the following: (i) how many
of the dosage forms listed were deemed suitable for chil-
dren at the age and dose recommended; and (ii) whether
the dosage forms listed were available in the UK. For this
analysis, an ‘age-appropriate’ dosage form was defined
as [abbreviated] ‘a dosage form for which a child of a speci-
fied age would have the natural ability to use . . . without
the product having to be altered from its original
“intended” presentation, prior to administration’ [66]. For
neonates, infants and young children, ∼30% of the prepa-
rations (dosage form and strength) in the MF were judged
as age appropriate, in contrast to 80% for older children
(aged 6–11 years). Surprisingly, 37% of the 340 assessed
medicinal products were not commercially available in
the UK, which suggests that access in LMICs may also be
challenging [66].
To overcome formulation-related issues, many people
(healthcare practitioners, parents or patients) have to
resort to manipulating the dosage form provided by,
for instance, tablet cutting/splitting/crushing/mixing/
dissolving [67, 68]. However, any manipulations (even
simply adding the drug to food) will usually have
unknown or unpredictable effects on the pharma-
cokinetics and pharmacodynamics [69], with associated
implications for therapeutic safety and efficacy [70]. Evi-
dence is typically sparse in these situations, and there are
few guidelines available [71, 72]. This is despite the fact
that some extemporaneous formulations can potentially
cause harm, including toxicity or therapeutic failure.
Adverse events may result from inaccurate dose admin-
istration, occurring when, for example, the drug is unsta-
ble in liquid formulation (e.g. isoniazid [73]). However,
developing age-specific formulations is expensive, so
these problems persist [74]. It must also be remembered
that access to multiple formulations of different strengths
can potentially increase the risk of medication errors [75].
In the LMIC setting, the provision of open-access guide-
lines to help standardize the approach to intravenous
medicines administration and extemporaneous prepara-
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tions of commonly used medicines could help avoid
some of these associated risks.
Conclusions
There is an urgent need to improve the quality of antibiotic
prescribing throughout the world, particularly in resource-
poor settings. In view of the growing threat posed by AMR,
this has become a global health priority. The development
of sound research methodology to capture antibiotic pre-
scribing data from different countries has been a signifi-
cant step forward, and there is now an opportunity to use
global point prevalence surveys as a tool to monitor and
improve prescribing internationally. Feeding back point
prevalence survey results to individual institutions allows
local teams to make meaningful comparisons of their pre-
scribing practice with that of others and to identify markers
of good-quality antimicrobial prescribing and strategies
for improvement, including antimicrobial stewardship [76,
77]. Stewardship programmes in the paediatric context
have been shown to reduce the length of hospital stay and
also have pharmacoeconomic benefits [78], and imple-
mentation in LMICs is encouraged by the WHO [2]. To date,
however, it has become clear that altering clinicians’ pre-
scribing habits takes time, and the importance of educa-
tion and training is paramount. Rational prescribing, AMR
and stewardship must be emphasized in both undergradu-
ate and postgraduate teaching programmes, as well as
in primary and secondary care. Studies in the resource-
poor setting should focus on developing cheap and simple
stewardship programmes. These initiatives are currently
too costly, which makes any progress challenging in the
current economic climate. With appropriate use of open-
access resources and effective dissemination of this infor-
mation, the resulting changes in antimicrobial prescribing
policy and practice have the potential to bring great ben-
efits to children around the world.
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Appendix 1
World Health Organization Essential Medicines list of anti-infective
agents 2011 [37]
Essential Complimentary Other agents
Amoxicillin, amoxicillin and
clavulanic acid, benzathine
benzylpenicillin, benzylpenicillin,
cephalexin, cefazolin,
ceftriaxone, cloxacillin,
phenoxymethylpenicillin,
azithromycin, chloramphenicol,
ciprofloxacin, doxycycline,
erythromycin, gentamicin,
metronidazole, nitrofurantoin,
co-trimoxazole, trimethoprim
Cefotaxime,
ceftazidime,
cilastatin,
clindamycin,
imipenem and
vancomycin
Antituberculosis
antibiotics:
rifampicin, isoniazid,
streptomycin,
ethambutol,
pyrazinamide
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